{"id":3079,"date":"2023-09-26T22:38:55","date_gmt":"2023-09-26T20:38:55","guid":{"rendered":"https:\/\/blogs.sun.ac.za\/dttc\/?page_id=3079"},"modified":"2023-10-24T17:15:57","modified_gmt":"2023-10-24T15:15:57","slug":"benefit-kids-formulation-development","status":"publish","type":"page","link":"https:\/\/blogs.sun.ac.za\/dttc\/benefit-kids-formulation-development\/","title":{"rendered":"BENEFIT Kids | Formulation Development"},"content":{"rendered":"
\n
\n\t

Improving the availability of child-friendly formulations of 2nd-line TB drugs<\/b><\/p>\n

Led by TB Alliance and in partnership with Stellenbosch University, the BENEFIT Kids project is working closely with generic manufacturers to accelerate progress and ensure the development of novel or optimised formulations of two key drugs, moxifloxacin and linezolid, to ensure that formulations are child-friendly and palatable. As part of this work, a study of the best tasting formulation blend of these drugs (ChilPref_ML) was successfully completed in healthy child volunteers in South Africa in 2022. The results, to be disseminated in 2023, have informed the taste selection of these new formulations.\u00a0 We will continue to build on this work and undertake more field work on optimal and practical delivery methods of TB medications to children.<\/span><\/p>\n<\/div>\n<\/div><\/div><\/div>

\n\t\t\t\t\t\t\t

\n\t\t\t\t\t\tBENEFIT Kids: The ChilPref ML Study\t\t\t\t\t\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n<\/div><\/div>
\n